Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Related Articles
FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
Highlights of ASH in North America
Join the world’s leading hematology experts at Highlights of ASH in North America, a two-day program offered in multiple locations that highlights the most influential…
Results for TAR-200 + Cetrelimab in Muscle-Invasive Bladder … : Oncology Times
An abstract is unavailable.
Lete-Cel Generates Durable Responses in Synovial Sarcoma and Myoxid/Round Cell Liposarcoma
Patients with metastatic myxoid/round cell liposarcoma or synovial sarcoma expressing NY-ESO-1 and HLA achieved an ORR of 42% with lete-cel.
Giving Tuesday Campaign
We’re addressing an important issue that affects many people. Our mission is to spread awareness and raise money for solutions we have identified. We created…
PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Macrophages with elevated HMOX1 expression are enriched in PTEN-deficient high-grade serous ovarian carcinoma, promote tumor growth, and represent a potential therapeutic target.
Myasthenia Gravis Research Highlights: AAN 2024
Nicholas Silvestri, MD, of the Univ of Buffalo, provides an overview of the latest myasthenia gravis clinical research presented at AAN 2024.
Research and trials hold the promise to stop lung cancer
A world-renowned lung cancer specialist @OSUCCC_James continues developing research and clinical trials that hold promise to stop lung cancer.
IASLC Academy | IASLC
The IASLC Academy is a prestigious program geared toward early-career physicians worldwide who aspire to pursue academic careers in thoracic oncology.
Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors
The CHMP has recommended repotrectinib for ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors.